Home » Stocks » PRAH

PRA Health Sciences, Inc. (PRAH)

Stock Price: $170.67 USD -1.63 (-0.95%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 11.06B
Revenue (ttm) 3.33B
Net Income (ttm) 213.32M
Shares Out 64.15M
EPS (ttm) 3.27
PE Ratio 52.19
Forward PE 28.49
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $170.67
Previous Close $172.30
Change ($) -1.63
Change (%) -0.95%
Day's Open 171.56
Day's Range 170.58 - 172.12
Day's Volume 522,315
52-Week Range 86.86 - 173.13

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.

6 days ago - Zacks Investment Research

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of PRA Health Science...

1 week ago - Business Wire

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.75% and 9.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of PRA Health Sciences (NASDAQ:PRAH) fell after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% year over year to $1.35, which beat the estimate of $1.34.

1 week ago - Benzinga

RALEIGH, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended March 31, 2021.

1 week ago - GlobeNewsWire

Here we discuss three MedTech subsectors, which encourage us with their consistency through the pandemic year and are likely to have continued with their winning streak in Q121.

Other stocks mentioned: HOLX, PKI
2 weeks ago - Zacks Investment Research

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements PRA offers post-authorization safety solutions to keep up with...

2 weeks ago - GlobeNewsWire

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

Other stocks mentioned: ALGN, ICLR, STE, TDOC, TMO, XRAY
3 weeks ago - Zacks Investment Research

PRA Health Sciences (PRAH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incr...

3 weeks ago - Zacks Investment Research

PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.

3 weeks ago - Zacks Investment Research

Maryland-based physicians can quickly deploy remote care options for patients with PRA's digital health technology Maryland-based physicians can quickly deploy remote care options for patients with PRA'...

3 weeks ago - GlobeNewsWire

PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.

Other stocks mentioned: MRK
1 month ago - Zacks Investment Research

PRA's cloud-based infrastructure enables Merck KGaA, Darmstadt, Germany to deliver a better product experience and scale for future enhancements PRA's cloud-based infrastructure enables Merck KGaA, Darm...

1 month ago - GlobeNewsWire

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.

1 month ago - Zacks Investment Research

Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify risks to the efficiency and success of their trials Four-part, patient-focused toolkit is availabl...

1 month ago - GlobeNewsWire

NEW YORK, March 11, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning p...

Other stocks mentioned: MIK, SVBI, TLND, WSFS
1 month ago - PRNewsWire

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

2 months ago - Zacks Investment Research

NEW YORK, Feb. 27, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Act...

2 months ago - PRNewsWire

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

Other stocks mentioned: RTP, SFTW
2 months ago - GlobeNewsWire

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PRA Health Sciences Inc. ("PRAH" or the...

2 months ago - PRNewsWire

MILWAUKEE, Feb. 24, 2021 /PRNewswire/ -- Ademi LLP is investigating PRA Health (NASDAQ: PRAH) for possible breaches of fiduciary duty and other violations of law in its transaction with Icon. Click here...

2 months ago - PRNewsWire

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other stocks mentioned: PSTX, SLRX, SNSS
2 months ago - Benzinga

The company released its fourth-quarter earnings report, but that doesn't tell the whole story.

2 months ago - The Motley Fool

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PRA Health S...

Other stocks mentioned: ICLR
2 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PRA Health Sciences, Inc. (NASDAQ: PRAH) to ICON plc is fair to PRA Health shareholde...

2 months ago - Business Wire

Shares of PRA Health Sciences (NASDAQ:PRAH) rose 20.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 0.65% year over year to $1.55, which beat th...

2 months ago - Benzinga

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 5.44% and 5.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ICON plc (NASDAQ: ICLR) has agreed to acquire PRA Health Sciences Inc (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion. The per-share consideration consists of $80 in c...

2 months ago - Benzinga

RALEIGH, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us," or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended December 3...

2 months ago - GlobeNewsWire

DUBLIN--(BUSINESS WIRE)--ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research

Other stocks mentioned: ICLR
2 months ago - Business Wire

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 202...

3 months ago - GlobeNewsWire

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction TreatmentToronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sc...

3 months ago - Newsfile Corp

PRA's remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality PRA's remote patient mon...

4 months ago - GlobeNewsWire

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.

Other stocks mentioned: DXCM, TDOC
5 months ago - Zacks Investment Research

Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA's industry-leading DCT practice Dr. Isaac Rodriguez-Chavez brings vast expertise in reg...

5 months ago - GlobeNewsWire

PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

6 months ago - Zacks Investment Research

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 15.04% and 3.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us" or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter ended September 30, 2020.

6 months ago - GlobeNewsWire

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

RALEIGH, N.C., Oct. 07, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its third quarter 2020 results after the market closes on Wednesday, November 4, 2020. The Company ...

7 months ago - GlobeNewsWire

With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health

7 months ago - GlobeNewsWire

PRA Health Sciences: A Solid Investment Case But Watch Out For Signs Of Inertia

7 months ago - Seeking Alpha

PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.

7 months ago - Zacks Investment Research

Asian countries have already shown clear signs of major economic recession.

Other stocks mentioned: DGX, LH, MDRX, TMO, VEEV, ZM
7 months ago - Zacks Investment Research

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials The two companies bring tog...

7 months ago - GlobeNewsWire

RALEIGH, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) today announced the appointment of Glen Stettin, M.D. to the Board of Directors of the Company, effective Sept...

7 months ago - GlobeNewsWire

About PRAH

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance,... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 13, 2014
CEO
Colin Shannon
Employees
18,100
Stock Exchange
NASDAQ
Ticker Symbol
PRAH
Full Company Profile

Financial Performance

In 2020, PRAH's revenue was $3.18 billion, an increase of 3.82% compared to the previous year's $3.07 billion. Earnings were $197.04 million, a decrease of -18.92%.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for PRAH stock is "Buy." The 12-month stock price forecast is 170.00, which is a decrease of -0.39% from the latest price.

Price Target
$170.00
(-0.39% downside)
Analyst Consensus: Buy